Cancer Research Technology
Log in Register
Menu

Info

Catalogue Number 151026
Applications FACS IHC IF IP Fn
Antigen/Gene or Protein Targets Fc-gamma receptor 1 (FCGR1, CD64)
Synonyms Fc Fragment Of IgG Receptor Ia; Fc Gamma Receptor Ia; Fc-Gamma RIA; IGFR1; FCRI; Fc Gamma Receptor; CD64 Antigen; FCGR1; CD64; FCG1
Reactivity Human
Relevance
RECENTLY UPDATED
Anti-FCGR1 can mediate antibody dependant monocyte lysis of tumour cells (or cells expressing the antibody) using host cytotoxic mechanisms or be directed to different types of tumour cells in the form of a heteroantibody, mediating lysis.

Background

Was created by Nancy Hogg at the London CRUK research institute: Lincoln’s Inn Fields, in order to mediate monocyte mediated antibody dependent lysis/death of cells/hybridomas expressing FCGR1 for IgG1. This means that high affinity FcR1 on monocytes can be used as a cytotoxic trigger to destroy targeted tumour cells expressing the antibody or heteroantibodies can be produced and used to target tumour cells which don’t express anti-FCGR1.

Research Application
Many uses across a range of applications, especially immunotherapy and inflammation.
Involved in both innate and adaptive immune responses, cytokine production and phagocytosis.

Fc-gamma receptor 1 (CD64) is an IgG receptor expressed by monocytes and myeloid cell lines. It is a marker of inflammation. It is involved in cancer and many chronic diseases (arthritis, multiple sclerosis, diabetic ulcers), but also in antibody-dependent cell-mediated cytotoxicity (ADCC), sepsis, automimmune disorders and periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome. The 10.1 antibody blocks the Ig binding to FcR1 receptor.
Host Mouse
Immunogen Rheumatoid synovial fluid cells and fibronectin purified human monocytes.
Immunogen UniProt ID
RECENTLY UPDATED
P12314
Positive Control Myeloid cell lines U937 and HL60
Subclass IgG1
Molecular Weight (kDa) 71
Myeloma Used Sp2/0-Ag14
Recommended Growing Conditions DMEM + 5% FCS
Strain Balb/c
Notes
RECENTLY UPDATED
Original Antibody Development
Hybridoma selected for high quantities of surface anti-FCGR1 via flow cytometry. Antibodies purified from ascitic fluid by precipitation, then high pressure chromatography.
A monoclonal antibody derived from U937 cells which were treated and injected intraperitoneally four times every four weeks, with the last two injections using U937 cells treated with IFNg (to increase Fc receptor yield). Splenocytes were fused with cells of NS-1 myeloma line.

Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Supplied in PBS containing 0.02% Sodium Azide.
Store undiluted between 2 and 8 degrees C, do not freeze and protect from prolonged light exposure.

Points of Interest
Anti FCGR1 doesn’t prevent the natural ligand (IgG) binding to monocytes at FCGR1, as this monoclonal antibody binds with the receptor at an epitope outside of the binding site. This demonstrates that the binding site doesn’t need to be occupied in order to cause human monocytes to kill tumour cells via ADCC.
Using anti-FCGR1 and a second-anti mouse reagent it is possible to see that the release of superoxide anion from monocytes requires bridging of FCGR1– cross linking of receptors may also trigger tumour cell cytotoxicity via the monocyte.
Anti-FCGR1 has high specificity to FCGR1 in triggering cytotoxicity, as cells linked to monocytes via different monocyte surface markers are not killed.
FCGR1 binds monomeric IgG with high affinity and interacts with an accessory G chain with an immunoreceptor tyrosine-based activation motif (ITAM) to trigger cell activation. It is expressed on monocytes, macrophages and myeloid cells, but expression on granulocytes can be induced via G-CSF or IFN G.
FCGR1 cross linking on monocytes can lead to clathrin mediated endocytosis.
Hybridoma cells expressing IgG directed to FCGR1 were efficiently lysed by human monocytes via monocyte mediated antibody dependant cytotoxicity, with the cytotoxicity of anti-FCGR1 bearing hybridoma cell line being inhibited by soluble antibody
Excessive FcgR1 activation leads to inflammation.
Hybridoma cells/cells expressing anti-FCGR1 antibody form extensive receptor cross linking with receptors on monocyte cell surface, leading to antibody dependant lysis via monocyte – this can be used for cytolysis of tumour cells. This antibody can be directed to the surface of other types of tumour cells by conjugating it to an anti-tumour specific antibody – this ‘heteroantibody’ could then bridge tumour cells to the monocytes via FCGR1 and hopefully mediate monocyte mediated antibody dependant lysis of these cells, using host cytotoxic mechanisms. Human IgG or other immune systems would not compromise the binding given it binds to a differing epitope.

Concentration
0.97 mg/mL
Research Area Cancer, Immunology

References

There are 30 reference entries for this reagent.

View All References

References: 30 entries
RECENTLY UPDATED

Onuora et al. 2019. Nat Rev Rheumatol. 15(8):450. PMID: 31278378.

Sips et al. 2016. Mucosal Immunol. :. PMID: 26883728.

Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies.

Europe PMC ID: 26883728

Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing.

Europe PMC ID: 26763072

Tan et al. 2016. Eur J Immunol. :. PMID: 26763072.

FACS

Vascular Health Profile predicts cardiovascular outcomes in patients with diabetes.

Europe PMC ID: 26566003

Hanihara et al. 2015. J Neurosurg. :1-8. PMID: 26636389.

Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.

Europe PMC ID: 26636389

Rogers et al. 2015. Cytometry B Clin Cytom. :. PMID: 26566003.

Tutt et al. 2015. J Immunol. :. PMID: 26512139.

FACS

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.

Europe PMC ID: 26512139

Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice.

Europe PMC ID: 26456831

Schwab et al. 2015. Cell Rep. :. PMID: 26456831.

Sousa et al. 2015. Breast Cancer Res. 17(1):101. PMID: 26243145.

FACS

Human breast cancer cells educate macrophages toward the M2 activation status.

Europe PMC ID: 26243145

Conrad et al. 2015. Arthritis Res Ther. 17:179. PMID: 26178906.

FACS

In vivo pre-activation of monocytes in patients with axial spondyloarthritis.

Europe PMC ID: 26178906

Up-regulation of CD64-expressing monocytes with impaired FcγR function reflects disease activity in polyarticular psoriatic arthritis.

Europe PMC ID: 26084203

Matt et al. 2015. Scand J Rheumatol. :1-10. PMID: 26084203.

Pilling et al. 2015. PLoS One. 10(3):e0119709. PMID: 25774777.

Sutherland et al. 2015. Curr Protoc Cytom. 72:6.37.1-6.37.29. PMID: 25827482.

High-Sensitivity Detection of PNH Red Blood Cells, Red Cell Precursors, and White Blood Cells.

Europe PMC ID: 25827482

The long pentraxin PTX3 promotes fibrocyte differentiation.

Europe PMC ID: 25774777

Mancardi et al. 2013. Blood. 121(9):1563-73. PMID: 23293080.

Schleinitz et al. 2008. Arthritis Rheum. 58(10):3216-23. PMID: 18821690.

Expression of the CD85j (leukocyte Ig-like receptor 1, Ig-like transcript 2) receptor for class I major histocompatibility complex molecules in idiopathic inflammatory myopathies.

Europe PMC ID: 18821690

Jayaram et al. 1989. Clin Exp Immunol. 75(3):414-20. PMID: 2495203.

The Fc receptor, FcRI, and other activation molecules on human mononuclear phagocytes after treatment with interferon-gamma.

Europe PMC ID: 2495203

Dougherty et al. 1987. Eur J Immunol. 17(10):1453-9. PMID: 3500057.

The human mononuclear phagocyte high-affinity Fc receptor, FcRI, defined by a monoclonal antibody, 10.1.

Europe PMC ID: 3500057


Add a reference

References: 30 entries
RECENTLY UPDATED

Onuora et al. 2019. Nat Rev Rheumatol. 15(8):450. PMID: 31278378.

Sips et al. 2016. Mucosal Immunol. :. PMID: 26883728.

Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies.

Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing.

Tan et al. 2016. Eur J Immunol. :. PMID: 26763072.

FACS

Vascular Health Profile predicts cardiovascular outcomes in patients with diabetes.

Hanihara et al. 2015. J Neurosurg. :1-8. PMID: 26636389.

Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.

Rogers et al. 2015. Cytometry B Clin Cytom. :. PMID: 26566003.

Tutt et al. 2015. J Immunol. :. PMID: 26512139.

FACS

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.

Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice.

Schwab et al. 2015. Cell Rep. :. PMID: 26456831.

Sousa et al. 2015. Breast Cancer Res. 17(1):101. PMID: 26243145.

FACS

Human breast cancer cells educate macrophages toward the M2 activation status.

Conrad et al. 2015. Arthritis Res Ther. 17:179. PMID: 26178906.

FACS

In vivo pre-activation of monocytes in patients with axial spondyloarthritis.

Up-regulation of CD64-expressing monocytes with impaired FcγR function reflects disease activity in polyarticular psoriatic arthritis.

Matt et al. 2015. Scand J Rheumatol. :1-10. PMID: 26084203.

Pilling et al. 2015. PLoS One. 10(3):e0119709. PMID: 25774777.

Sutherland et al. 2015. Curr Protoc Cytom. 72:6.37.1-6.37.29. PMID: 25827482.

High-Sensitivity Detection of PNH Red Blood Cells, Red Cell Precursors, and White Blood Cells.

The long pentraxin PTX3 promotes fibrocyte differentiation.

Mancardi et al. 2013. Blood. 121(9):1563-73. PMID: 23293080.

Schleinitz et al. 2008. Arthritis Rheum. 58(10):3216-23. PMID: 18821690.

Expression of the CD85j (leukocyte Ig-like receptor 1, Ig-like transcript 2) receptor for class I major histocompatibility complex molecules in idiopathic inflammatory myopathies.

Jayaram et al. 1989. Clin Exp Immunol. 75(3):414-20. PMID: 2495203.

The Fc receptor, FcRI, and other activation molecules on human mononuclear phagocytes after treatment with interferon-gamma.

Dougherty et al. 1987. Eur J Immunol. 17(10):1453-9. PMID: 3500057.

The human mononuclear phagocyte high-affinity Fc receptor, FcRI, defined by a monoclonal antibody, 10.1.


Add a reference